Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Serin

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
The Oncologist|May 22, 2012
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trialBruno Coudert, Bernard Asselain, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialHenri Roché, Pierre Fumoleau, Marc Spielmann, et al.
Breast Cancer Research and Treatment|March 29, 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trialsElie Rassy, Thomas Filleron, Alessandro Viansone, et al.
The Lancet. Oncology|June 15, 2013
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trialMarc Spielmann, Henri Roché, Thierry Delozier, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroupVéronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Lancet (London, England)|June 11, 2019
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
Breast Cancer Research and Treatment|November 4, 2011
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewElisabeth Luporsi, Fabrice André, Frédérique Spyratos, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
The Oncologist|May 22, 2012
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trialBruno Coudert, Bernard Asselain, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialHenri Roché, Pierre Fumoleau, Marc Spielmann, et al.
Breast Cancer Research and Treatment|March 29, 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trialsElie Rassy, Thomas Filleron, Alessandro Viansone, et al.
The Lancet. Oncology|June 15, 2013
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trialMarc Spielmann, Henri Roché, Thierry Delozier, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroupVéronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Lancet (London, England)|June 11, 2019
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
Breast Cancer Research and Treatment|November 4, 2011
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewElisabeth Luporsi, Fabrice André, Frédérique Spyratos, et al.
Pageof 4